Table 7.
Repeated Measures Analysis of Variance. Effect of Treatments on NAFLD Scores (assessed by CAP value) by, Time and NAFLD Severity. NutriAtt Trial, Castellana Grotte, 2015–2016.
| NAFLD a | ||||
|---|---|---|---|---|
| Moderate | Severe | |||
| CAP b | Contrast | (CI 95%) | Contrast | (CI 95%) |
| (45 days vs. base) C c | −15.50 | (−64.02; 33.02) | −8.73 | (−45.28; 27.81) |
| (90 days vs. base) C c | −29.00 | (−77.52; 19.52) | −21.82 | (−61.38; 17.73) |
| (45 days vs. base) LGIMD d | −13.80 | (−66.96; 39.36) | −54.27 | (−85.89; −22.64) ** |
| (90 days vs. base) LGIMD d | −22.65 | (−80.58; 35.28) | −39.13 | (−72.53; −5.73) * |
| (45 days vs. base) PA1 e | −6.67 | (−55.19; 41.86) | −51.36 | (−84.09; −18.62) * |
| (90 days vs. base) PA1 e | 10.67 | (−37.86; 59.19) | −72.77 | (−108.69; −36.85) ** |
| (45 days vs. base) PA2 f | 18.14 | (−26.78; 63.07) | −55.73 | (−87.35; −24.11) ** |
| (90 days vs. base) PA2 f | 18.40 | (−29.24; 66.05) | −77.70 | (−112.16; −43.24) ** |
| (45 days vs. base) PA1 + LGIMD g | −23.75 | (−65.77; 18.27) | −68.53 | (−100.15; −36.91) ** |
| (90 days vs. base) PA1 + LGIMD g | −23.09 | (−37.31; 21.13) | −83.27 | (−117.72; −48.81) ** |
| (45 days vs. base) PA2 + LGIMD h | −27.4 | (−64.99; 10.19) | −39.14 | (−71.87; −6.41) * |
| (90 days vs. base) PA2 + LGIMD h | −46.31 | (−85.43; −7.19) * | −32.57 | (−66.23; 1.09) |
a NAFLD: Non-Alcoholic Fatty Liver Disease; b CAP: Controlled Attenuation Parameter Measured by FibroScan®; c C: Control Diet; d LGIMD: Low Glycemic Index Mediterranean Diet; e PA1: Aerobic Activity Program; f PA2: Combined Activity Program; g PA1 + LGIMD; h PA2 + LGIMD. * p-Value < 0.05; ** p-Value < 0.001.